Plasma levels of mannan-binding lectin (MBL)-associated serine proteases (MASPs) and MBL-associated protein in cardio- and cerebrovascular diseases

Clinical and Experimental Immunology - Tập 173 Số 1 - Trang 112-120 - 2013
V. Frauenknecht1, Steffen Thiel2, Line Storm2, Niklaus Meier3, Maria Arnold3, JP Schmid4, Hugo Saner4, Verena Schroeder1
1University Clinic of Haematology, Haemostasis Research Laboratory, University Hospital and University of Bern, Bern, Switzerland
2Department of Biomedicine, Aarhus University, Aarhus, Denmark
3Department of Neurology, University Hospital and University of Bern, Switzerland
4Department of Cardiology, Cardiovascular Prevention, Rehabilitation and Sports Cardiology Unit, University Hospital and University of Bern, Bern, Switzerland

Tóm tắt

Summary Growing evidence suggests a prominent role of the complement system in the pathogenesis of cardio- and cerebrovascular diseases (CVD). Mannan-binding lectin-associated serine proteases (MASPs) MASP-1 and MASP-2 of the complement lectin pathway contribute to clot formation and may represent an important link between inflammation and thrombosis. MBL-associated protein MAp44 has shown cardioprotective effects in murine models. However, MAp44 has never been measured in patients with CVD and data on MASP levels in CVD are scarce. Our aim was to investigate for the first time plasma levels of MAp44 and MASP-1, -2, -3 concomitantly in patients with CVD. We performed a pilot study in 50 healthy volunteers, in stable coronary artery disease (CAD) patients with one-vessel (n = 51) or three-vessel disease (n = 53) and age-matched controls with normal coronary arteries (n = 53), 49 patients after myocardial infarction (MI) and 66 patients with acute ischaemic stroke. We measured MAp44 and MASP-1 levels by in-house time-resolved immunofluorometric assays. MASP-2 and MASP-3 levels were measured using commercial enzyme-linked immunosorbent assay kits. MASP-1 levels were highest in subacute MI patients and lowest in acute stroke patients. MASP-2 levels were lower in MI and stroke patients compared with controls and CAD patients. MASP-3 and MAp44 levels did not differ between groups. MASP or MAp44 levels were not associated with severity of disease. MASP and MAp44 levels were associated with cardiovascular risk factors including dyslipidaemia, obesity and hypertension. Our results suggest that MASP levels may be altered in vascular diseases. Larger studies are needed to confirm our results and elucidate the underlying mechanisms.

Từ khóa


Tài liệu tham khảo

Libby, 2009, Inflammation in atherosclerosis, J Am Coll Cardiol, 54, 2129, 10.1016/j.jacc.2009.09.009

Carter, 2005, Inflammation, thrombosis and acute coronary syndromes, Diab Vasc Dis Res, 2, 113, 10.3132/dvdr.2005.018

Oksjoki, 2007, Function and regulation of the complement system in cardiovascular diseases, Front Biosci, 12, 4696, 10.2741/2419

Speidl, 2011, Complement in atherosclerosis: friend or foe?, J Thromb Haemost, 9, 428, 10.1111/j.1538-7836.2010.04172.x

Frauenknecht, 2012, Complement – a phylogenetically old system as a new player in the development of atherosclerosis [in German], Hämostaseologie, 32, 276, 10.5482/ha-1191

Banz, 2012, Role of complement and perspectives for intervention in ischemia-reperfusion damage, Ann Med, 44, 205, 10.3109/07853890.2010.535556

Markiewski, 2007, Complement and coagulation: strangers or partners in crime?, Trends Immunol, 28, 184, 10.1016/j.it.2007.02.006

Amara, 2010, Molecular intercommunication between the complement and coagulation systems, J Immunol, 185, 5628, 10.4049/jimmunol.0903678

Ricklin, 2010, Complement: a key system for immune surveillance and homeostasis, Nat Immunol, 11, 785, 10.1038/ni.1923

Hansen, 2010, Collectin 11 (CL-11, CL-K1) is a MASP-1/3-associated plasma collectin with microbial-binding activity, J Immunol, 185, 6096, 10.4049/jimmunol.1002185

Yongqing, 2012, Mannose-binding lectin serine proteases and associated proteins of the lectin pathway of complement: two genes, five proteins and many functions?, Biochim Biophys Acta, 1824, 253, 10.1016/j.bbapap.2011.05.021

Degn, 2011, Disease-causing mutations in genes of the complement system, Am J Hum Genet, 88, 689, 10.1016/j.ajhg.2011.05.011

Kidmose, 2012, Structural basis for activation of the complement system by C4 cleavage, Proc Natl Acad Sci USA, 109, 15425, 10.1073/pnas.1208031109

Degn, 2012, Mannan-binding lectin-associated serine protease (MASP)-1 is crucial for lectin pathway activation in human serum, whereas neither MASP-1 nor MASP-3 is required for alternative pathway function, J Immunol, 189, 3957, 10.4049/jimmunol.1201736

Héja, 2012, Revised mechanism of complement lectin-pathway activation revealing the role of serine protease MASP-1 as the exclusive activator of MASP-2, Proc Natl Acad Sci USA, 109, 10498, 10.1073/pnas.1202588109

Sirmaci, 2010, MASP1 mutations in patients with facial, umbilical, coccygeal, and auditory findings of Carnevale, Malpuech, OSA, and Michels syndromes, Am J Hum Genet, 87, 679, 10.1016/j.ajhg.2010.09.018

Rooryck, 2011, Mutations in lectin complement pathway genes COLEC11 and MASP1 cause 3MC syndrome, Nat Genet, 43, 197, 10.1038/ng.757

Skjoedt, 2010, MBL-associated serine protease-3 circulates in high serum concentrations predominantly in complex with ficolin-3 and regulates ficolin-3 mediated complement activation, Immunobiology, 215, 921, 10.1016/j.imbio.2009.10.006

Dahl, 2001, MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway, Immunity, 15, 127, 10.1016/S1074-7613(01)00161-3

Iwaki, 2011, The role of mannose-binding lectin-associated serine protease-3 in activation of the alternative complement pathway, J Immunol, 187, 3751, 10.4049/jimmunol.1100280

Degn, 2009, MAp44, a human protein associated with pattern recognition molecules of the complement system and regulating the lectin pathway of complement activation, J Immunol, 183, 7371, 10.4049/jimmunol.0902388

Skjoedt, 2012, Crystal structure and functional characterization of the complement regulator mannose-binding lectin (MBL)/ficolin-associated protein-1 (MAP-1), J Biol Chem, 287, 32913, 10.1074/jbc.M112.386680

Pavlov, 2012, Endogenous and natural complement inhibitor attenuates myocardial injury and arterial thrombogenesis, Circulation, 126, 2227, 10.1161/CIRCULATIONAHA.112.123968

Hajela, 2002, The biological functions of MBL-associated serine proteases (MASPs), Immunobiology, 205, 467, 10.1078/0171-2985-00147

Krarup, 2007, Simultaneous activation of complement and coagulation by MBL-associated serine protease 2, PLoS ONE, 2, e623, 10.1371/journal.pone.0000623

Krarup, 2008, The action of MBL-associated serine protease 1 (MASP1) on factor XIII and fibrinogen, Biochim Biophys Acta, 1784, 1294, 10.1016/j.bbapap.2008.03.020

Gulla, 2010, Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot, Immunology, 129, 482, 10.1111/j.1365-2567.2009.03200.x

Hess, 2012, Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation, PLoS ONE, 7, e35690, 10.1371/journal.pone.0035690

La Bonte, 2012, Mannose-binding lectin-associated serine protease-1 is a significant contributor to coagulation in a murine model of occlusive thrombosis, J Immunol, 188, 885, 10.4049/jimmunol.1102916

Trendelenburg, 2010, Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention, Eur Heart J, 31, 1181, 10.1093/eurheartj/ehp597

Osthoff, 2011, Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients, PLoS ONE, 6, e21338, 10.1371/journal.pone.0021338

Mellbin, 2012, Complement activation and prognosis in patients with type 2 diabetes and myocardical infarction, Diabetes Care, 35, 911, 10.2337/dc11-1642

Zhang, 2011, MASP-2 activation is involved in ischemia-related necrotic myocardial injury, Int J Cardiol, 10.1016/j.ijcard.2011.11.032

Cervera, 2010, Genetically-defined deficiency of mannose-binding lectin is associated with protection after experimental stroke in mice and outcome in human stroke, PLoS ONE, 5, e8433, 10.1371/journal.pone.0008433

Schroeder, 2002, Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography, Thromb Haemost, 88, 1020, 10.1055/s-0037-1613349

Schroeder, 2010, Coagulation factor XIII activation peptide and subunit levels in patients with acute ischemic stroke: a pilot study, Thromb Res, 126, e122, 10.1016/j.thromres.2010.05.027

Brott, 1989, Measurements of acute cerebral infarction: a clinical examination scale, Stroke, 20, 864, 10.1161/01.STR.20.7.864

Adams, 1993, Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment, Stroke, 24, 35, 10.1161/01.STR.24.1.35

Degn, 2010, Biological variations of MASP-3 and MAp44, two splice products of the MASP1 gene involved in regulation of the complement system, J Immunol Methods, 361, 37, 10.1016/j.jim.2010.07.006

Thiel, 2012, Mannan-binding lectin (MBL)-associated serine protease-1 (MASP-1), a serine protease associated with humoral pattern-recognition molecules: normal and acute-phase levels in serum and stoichiometry of lectin pathway components, Clin Exp Immunol, 169, 38, 10.1111/j.1365-2249.2012.04584.x

Schwaeble, 2011, Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury, Proc Natl Acad Sci USA, 108, 7523, 10.1073/pnas.1101748108

Orsini, 2012, Targeting mannose-binding lectin confers long-lasting protection with a surprisingly wide therapeutic window in cerebral ischemia, Circulation, 126, 1484, 10.1161/CIRCULATIONAHA.112.103051

Møller-Kristensen, 2003, Levels of mannan-binding lectin-associated serine protease-2 in healthy individuals, J Immunol Methods, 282, 159, 10.1016/j.jim.2003.08.012

Ytting, 2007, Biological variation in circulating levels of mannan-binding lectin (MBL) and MBL-associated serine protease-2 and the influence of age, gender and physical exercise, Scand J Immunol, 66, 458, 10.1111/j.1365-3083.2007.01991.x

Kohler, 2002, Insulin resistance syndrome: interaction with coagulation and fibrinolysis, Swiss Med Wkly, 132, 241

Cortesio, 2006, Mannan-binding lectin-associated serine protease 3 cleaves synthetic peptides and insulin-like growth factor-binding protein 5, Arch Biochem Biophys, 449, 164, 10.1016/j.abb.2006.02.006

Fischer, 2004, Associations of insulin-like growth factors, insulin-like growth factor binding proteins and acid-labile subunit with coronary heart disease, Clin Endocrinol (Oxf), 61, 595, 10.1111/j.1365-2265.2004.02136.x

Conti, 2011, IGF-1 and atherothrombosis: relevance to pathophysiology and therapy, Clin Sci, 120, 377, 10.1042/CS20100400

Thông tin
Thông tin xuất bản

Clinical and Experimental Immunology

Tập 173 Số 1

112-120

Thông tin tác giả